logo
logo

Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic

Jan 07, 2021•over 4 years ago

Amount Raised

$72 Million

Round Type

series b

Cambridge

Description

 Werewolf Therapeutics, Inc., an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments, today announced the completion of its $72 million Series B financing. The proceeds from the Series B financing will advance Werewolf's lead INDUKINE™ product candidates, WTX-124 (interleukin-2, or IL-2) and WTX-330 (interleukin-12, or IL-12) through Phase 1 clinical proof-of-concept studies, and progress additional programs to Investigational New Drug application-readiness.  INDUKINE™ molecules are a novel class of systemically delivered, conditionally activated proinflammatory immune modulators.

Company Information

Company

Werewolf Therapeutics, Inc.

Location

Cambridge, Maryland, United States

About

Werewolf Therapeutics, Inc. is an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments designed to focus the body's immune response to selectively target cancer. Werewolf's proprietary PREDATOR™ protein engineering platform combines a variety of approaches to actively silence the drug while in systemic circulation, optimize its pharmacokinetic profile, and rapidly and efficiently transform into the fully active state upon reaching the tumor microenvironment for maximum therapeutic potential. Werewolf is creating a new era of tumor-selective, systemically delivered drugs with the potential to deliver more effective, less toxic treatments for people with cancer. To learn more visit www.werewolftx.com.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech